Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Operating Expenses (2018 - 2025)

Historic Operating Expenses for Inmune Bio (INMB) over the last 7 years, with Q3 2025 value amounting to $7.4 million.

  • Inmune Bio's Operating Expenses fell 3950.02% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.4 million, marking a year-over-year increase of 2365.29%. This contributed to the annual value of $42.6 million for FY2024, which is 4265.79% up from last year.
  • Latest data reveals that Inmune Bio reported Operating Expenses of $7.4 million as of Q3 2025, which was down 3950.02% from $24.6 million recorded in Q2 2025.
  • Over the past 5 years, Inmune Bio's Operating Expenses peaked at $24.6 million during Q2 2025, and registered a low of $4.6 million during Q1 2021.
  • For the 5-year period, Inmune Bio's Operating Expenses averaged around $9.0 million, with its median value being $8.4 million (2023).
  • Examining YoY changes over the last 5 years, Inmune Bio's Operating Expenses showed a top increase of 14907.25% in 2025 and a maximum decrease of 3950.02% in 2025.
  • Quarter analysis of 5 years shows Inmune Bio's Operating Expenses stood at $9.2 million in 2021, then tumbled by 37.57% to $5.7 million in 2022, then skyrocketed by 46.49% to $8.4 million in 2023, then rose by 12.61% to $9.5 million in 2024, then dropped by 21.49% to $7.4 million in 2025.
  • Its last three reported values are $7.4 million in Q3 2025, $24.6 million for Q2 2025, and $10.0 million during Q1 2025.